Press Releases

 
Press Releases
  Date Title and Summary View
Feb 19, 2015
HAYWARD, Calif., Feb. 19, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update on the progress of the Company's development programs at the 35th Annual Cowen & Company Health Care Conference. Anthera will present from 10:00...
Feb 10, 2015
HAYWARD, Calif., Feb. 10, 2015 /PRNewswire/ -- Anthera Pharmaceuticals (NASDAQ: ANTH) today announced that the company has received formal notification from the Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity or maint...
Feb 10, 2015
HAYWARD, Calif., Feb. 10, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted...
Jan 7, 2015
HAYWARD, Calif., Jan. 7, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer. "We're fortunate to have Klara join our team as we enter this phase of our product development efforts," said Paul F. Truex, Anthera's President...
Dec 30, 2014
HAYWARD, Calif., Dec. 30, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it is inviting its shareholders and investors to a symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA. "Right Patient, Right Therapy"A Symposium on Syste...
Dec 15, 2014
HAYWARD, Calif., Dec. 15, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Anthera and Zenyaku Kogyo Co., Ltd. of Tokyo, Japan executed an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in Japan and potentially other countries throughout Asia.  Anthera retains f...
Nov 23, 2014
HAYWARD, Calif., Nov. 23, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2014 Annual Piper Jaffray Healthcare Conference. Anthera will present at 4:30PM ET, December 3rd, at the Palace Hotel in New York City....
Nov 20, 2014
HAYWARD, Calif., Nov. 20, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced today it has signed a manufacturing and supply agreement with the Patheon® division of DPx Holdings B.V.  The contract provides for Patheon to support the production of the Sollpura® clinical drug product for Anthera's Phase III registrat...
Nov 14, 2014
HAYWARD, Calif., Nov. 14, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the third quarter ended September 30, 2014. Net loss for the three months ended September 30, 2014 was $7.0 million, compared to $5.8 million for the same period in 2013. The increase in n...
Oct 1, 2014
HAYWARD, Calif., Oct. 1, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States. Anthera does not intend to communicate further regarding these discussions unless and until ...
Page:
1
... NextLast
= add release to Briefcase
JoomShaper